Kornimate/medical-research-clean huggingface dataset:
kosmos trio and ejection fraction pivotal study

Conditions: Cardiac Disease

Summary: this is a single-group, observational study which will involve obtaining two echo scans of recruited patients. all recruited patients will undergo echo scans by both novice users (nurses) and experts (echo sonographers). image quality between novices and experts as well as the ability to calculate lvef from novice and expert scans and the quality of the lvef calculated via kosmos-ef compared to lvef calculations by expert cardiologists will occur in post-hoc echo image analysis


Eligibility criteria:
inclusion criteria: * aged 18-89 years of age * have capacity to provide written consent either themselves or via healthcare proxy as determined by subjects' clinical care teams * have an anticipated timeline in the edou long enough to allow for completion of study procedures without causing delay to subjects' usual clinical care exclusion criteria: * heart rate \> 110 beats per minute at the time of recruitment * pregnant women * prior chest surgery * chest wall deformities or injuries (i.e. wounds, infections, etc) * limited mobility precluding them from turning in bed independently * speak a primary language other than english or spanish * vulnerable populations including: patients being evaluated for psychiatric crises, incarcerated individuals * unwilling or unable to consent to study procedures
innovative treatment for scarred vocal cords by local injection of autologous stromal vascular fraction

Conditions: Dysphonia

Summary: post-operative scarring on vocal cords is responsible for disorders of the vibration of the lining to the original dysphonia can be troublesome for the patient both in his private and professional life. there is no currently codified treatment for this type of situation and no therapeutic antifibrotic has been effective. cell therapy is a promising new approach.after a liposuction and removing of mature adipocytes (40 to 60%), the remaining cells called stromal vascular fraction (svf) could be isolated. svf consists of a heterogeneous cell population including multipotent stem cells similar to mesenchymal stem cells present in bone marrow. the investigators hypothesis is that the trophic and antifibrotic properties of svf could benefit patients with vocal cords scarring responsible for dysphonia.


Eligibility criteria:
inclusion criteria: * vocal difficulties felt as crippling (vhi \> 60/120) * presence of scar hurts of the caused vocal cords is by the initial surgery (micro-laryngoscopy in suspension with or without laser) or by a congenital pathology of glottidis sulcus * scar aspect of vocal cords judged on a stroboscopic examination * delay of at least 1 year with regard to the initial surgery exclusion criteria: * patients refusing the speech therapy * patients operated for a malignant lesion or in malignant potential serious dysplasia of the scar vocal cord * contraindication in the anesthesia * patients under anti-coagulants * patients presenting disorders of the coagulation * active infectious diseases
efficacy of cryotherapy in managing chemotherapy-induced peripheral neuropathy in children with leukemia

Conditions: Cancer

Summary: this study aimed to assess the efficacy of cryotherapy in controlling peripheral neuropathy in cancer children

peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. chemotherapy-induced peripheral neuropathy (cipn) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. pharmacists play a pivotal role in the prevention and management of cipn by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.peripheral neuropathy (pn) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (qol). prolonged symptoms associated with pn can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.

Eligibility criteria:
inclusion criteria: 1. their age will ranging from eight to seventeen years. 2. children participated in this study will from both sexes. 3. children receiving chemotherapy as medical treatment protocol 4. all children have polyneuropathy caused by chemotherapy. exclusion criteria: 1. children with epilepsy. 2. children with blood clotting disorder. 3. children have open wounds / broken skin 4. children with severe cardiac disease 5. uncooperative patients.
transcranial magnetic stimulation in children with attention deficit hyperactivity disorder (adhd). a safety study

Conditions: Attention Deficit Hyperactivity Disorder

Summary: low frequency repetitive transcranial magnetic stimulation(rtms) is a safe and tolerable procedure in children with attention deficit hyperactivity disorder(adhd); it also could be a complement to the treatment of patients with poor symptomatic control to conventional treatment.

attention deficit hyperactivity disorder is a common disorder in the infancy; the majority of adhd have good clinical response to amphetamines alone or in association with antiepileptic drugs. it is described that some patients(10-30%) with adhd do not respond to conventional pharmacological and psycho- pedagogical treatment; in those patients non invasive brain stimulation methods could be a supplementary option for symptomatic control. there are not many published papers describing the effects of rtms in persons younger than 18 years; so the first step to extent its use in pediatric population should be to obtain evidences about its tolerance and safety.

Eligibility criteria:
inclusion criteria: * ages eligible for study: 7years to 12 years * genders eligible for study: both exclusion criteria: * history of convulsions * co-morbidity with other psychiatric or neurologic disease

Keywords: children adhd rtms safety
survey on quality of life in myelodisplasia (squid)

Conditions: Myelodysplastic Syndromes

Summary: the purpose of this study is to evaluate the correlation between quality of life (qol) and hemoglobin in patients affected by myelodysplastic syndrome and to compare the mds (myelodisplastic syndrome) patient's self-assessed qol according to physician's evaluation

in low-risk myelodysplastic syndrome (mds), anemia is the major clinical problem and often represents the principal cause of symptoms which negatively influence quality of life (qol). moreover anemia has been associated with increased cardiac disease which, in older patients, may aggravate pre-existing conditions such as congestive heart failure. patients with mds often require red blood cell transfusions that further deteriorate patients' perception of well-being. this is an 18-month prospective observational investigation about the quality of life in myelodysplastic patients with the aim to evaluate the correlation between hemoglobin (hb) value and qol and to compare the mds patient's self-assessed qol per physician's assessment. one hundred and fifty consecutive mds patients at diagnosis and at least one with cytopenia - low level of hemoglobin or low level of neutrophils (a type of white blood cells that fights against infection) or low level of platelets (irregularly shaped cells found in blood that help prevent bleeding) - will be included in the evaluation. demographic and disease-specific data will be collected and qol will be evaluated by a specific questionnaire named qol-e which will be completed both by patients and respective physicians. study visits will be performed monthly until week 12; the subsequent visits will be performed at 6, 12 and 18 months. no serious adverse event will be collected during the study, only adverse reaction to any janssen-cilag drug should be reported. this information may be important to optimize treatment according to patients' preferences and expectations, to detect functional complications, as well as to improve communication between patients and caregivers. observational study - no study drug was administered.

Eligibility criteria:
inclusion criteria: * primary or secondary mds * at least one cytopenia according to international prognostic score system (ipss) criteria (hb \< 10 g/dl * absolute neutrophils count (a type of white cell that fights against infection) \< 1.800/µl * platelets (irregularly shaped cells found in blood that help prevent bleeding) \< 100.000/µl) * willing and able, based on investigator's judgment, to fill in qol questionnaires exclusion criteria: * refractory anemia with excess blasts (tumor cells located in the marrow \> 20%) * eastern cooperative oncology group performance status (ecog ps) \>3 * history of cerebrovascular disease with cognitive outcomes * psychiatric diseases or senile or vascular dementia * positive anamnesis for another clinically active tumor or when treatment has been stopped since less than 5 years

Keywords: myelodysplastic syndrome quality of life anemia epoetin alfa eprex
evaluation of the effects on the skin of different materials used in orogastric tube detection in premature babies

Conditions: Neonatal Skin Conditions

Summary: while medical adhesives provide fixation of devices and catheters in neonatal intensive care, they can cause disruption of skin integrity when removed. therefore, when detecting medical devices, it is important to choose products that will not harm babies' skin and to use different occlusive dressings (polymer foams, hydrogel dressings, hydrocolloid dressings). this study aims to compare the effectiveness of different types of patches (hydrocolloid dressing and hypoallergenic flexible patch) used in the detection of oragastric catheter (og) in preterm babies hospitalized in the neonatal intensive care unit in preventing skin damage.

many interventions are applied to premature babies in neonatal intensive care units due to the developing technologies in recent years. babies in neonatal intensive care need many devices to maintain their vital functions and monitor the treatment process. the medical adhesive materials to be selected are important in determining the medical devices used in neonatal intensive care units, especially premature babies. this study aims to compare the effectiveness of different types of patches (hydrocolloid dressing and hypoallergenic flexible patch) used in the detection of oragastric catheter (og) in preterm babies hospitalized in the neonatal intensive care unit in preventing skin damage.

Eligibility criteria:
inclusion criteria: * a newborn is a baby born between 32-36 weeks of gestation * no medical adhesive tape should be applied to the newborn's lips beforehand. * the newborn does not have any skin diseases * og will be inserted into the newborn for the first time * having a newborn receiving respiratory support with non-invasive mechanical ventilation, hood or free oxygen exclusion criteria: * the newborn is not a baby born between 32-36 weeks of gestation * applying medical adhesive tape on the newborn's lips beforehand * the newborn has any skin disease * og has been inserted into the newborn before and detected. * supporting and detecting the newborn's breathing by intubating it

Keywords: premature skin care hydrocolloid dressing hypoallergenic patch
effects of electroconvulsive therapy (ect) on serotonin-1a receptor binding

Conditions: Unipolar Depression

Summary: in treatment-resistant depression, electroconvulsive therapy (ect) has been shown to effectively reduce depressive symptoms, though the underlying neurobiological mechanism is still unclear. the serotonergic system, and in particular the inhibitory serotonin-1a (5-ht1a) receptor, appears to be significantly involved in the effectiveness of ect. the aim of the study is to assess the effects of ect on the 5-ht1a receptor binding potential (bpnd) and distribution in humans in vivo using positron emission tomography (pet) and the radioligand \[carbonyl-11c\]way-100635. 12 patients suffering from severe, therapy-resistant unipolar depression will undergo 3 pet scans, two of these scans taking place before the ect treatment, consisting of 6-14 ects, the third scan taking place after the ect treatment. this imaging study hypothesizes that upon completion of the ect, the overall 5-ht1a receptor bpnd in the brain of depressed patients will significantly change. this study would be the first to demonstrate an effect of electroconvulsive therapy on the 5-ht1a receptor binding in humans in vivo. given the involvement of the 5-ht1a receptor in the pathophysiology of mood disorders, the present study would be an important step towards a better understanding of antidepressant treatment and treatment response. by comparing treatment effect and the underlying biological mechanism, the study might help to identify biomarkers that distinguish patients who are likely to benefit from ect from patients who will rather be non-responders. finally, by investigating the role of the 5-ht1a receptor in ect, is highly discussed relevance for antidepressant action will be further elucidated and might prepare the ground for new therapeutic strategies.


Eligibility criteria:
inclusion criteria: * male or female * age 18 - 65 years * icd-10 diagnosis of severe unipolar depression (icd-10: f32.2, f32.3; f33.2, f33.3) * a score of 23 or greater on the 17-item ham-d * signed informed consent form * negative urine pregnancy test in women at the screening visit and at pet days * antidepressive and antipsychotic medication in a steady state for at least 10 days prior to inclusion * anesthesiological approval for ect exclusion criteria: * concomitant major internistic or neurological illness * clinically relevant abnormalities on a general physical examination and routine laboratory screening * current substance abuse, addiction * current or past history of schizophrenia or schizoaffective disorder * exposure to artificial radiation as volunteer in clinical studies within 10 years prior to inclusion into the present study * previous treatments with electroconvulsive therapy * treatment (\< 1 months before screening) with the following drugs: aripiprazole, risperidone, ziprasidone, clozapine, chlorpromazine, amitryptyline, nefazodone, trazodone, buspirone, pindolol, penbutolol, tertatolol, alprenolol, quetiapine * investigations using pet or spect within 10 years prior to the inclusion
covid-19 patients management during home isolation

Conditions: Covid19

Summary: the study will investigate management of covid-19 patients in home isolation.

a clinical trial concerned with the treatment of home isolated covid-19 patients

Eligibility criteria:
inclusion criteria: * covid-19 patients american society of anesthesiologists (asa) class i \>= 21 years old \<= 40 years old exclusion criteria: * not being consistent with home-isolation regimen
acute effects of interferential current on edema, pain and muscle strength in patients with distal radius fracture

Conditions: Radius Fractures; Edema; Pain

Summary: interferential current is a form of electrotherapy that is obtained by placing two different plates that produce medium frequency waveform current, resulting in a low frequency interferential waveform in deeper tissues. it was shown interferential current electrotherapy is beneficial for reduction of traumatic edema in tissues and pain control. patients with conservatively managed distal radius fractures were recruited after casts are shed, and were treated with one session(30 minutes) of different protocols of interferential current electrotherapy. before and after therapy, they were evaluated with volumetry, hand grip strength and visual analogue scale for pain.


Eligibility criteria:
inclusion criteria: * conservatively managed distal radius fractures exclusion criteria: * secondary conditions associated with edema(renal failure, congestive heart failure etc) * complex regional pain syndrome * compartment syndrome * contraindications for electrotherapy(cardiac pacemaker, thrombosis, pregnancy etc) * mental state unfit for electrotherapy * having treated with electrotherapy before

Keywords: radius fracture, interferential current, edema, pain
pain, acceptance, and discomfort with periodontally accelerated osteogenic orthodontics (paoo)

Conditions: Crowding of Anterior Mandibular Teeth

Summary: patients will be examined in the orthodontic department of the university of damascus dental school. patients who will be treated in conjunction with the paoo procedure and subjects who will meet the inclusion criteria will be included then the initial diagnostic records (diagnostic gypsum models, internal and external oral photographs, as well as radiographic images) will be studied to ensure that the selection criteria will be accurately matched. this study aims to assess patients' acceptance of the paoo procedure as well as the levels of pain and discomfort associated with this treatment.

surgical procedure associated with paoo the surgery will be performed under local anesthesia and then full-thickness flaps will be reflected labially only from the distal surface of the lower right canine to the distal surface of the lower left canine, after washing the exposed alveolar bone with saline, then a selective cortical cutting will be performed using a piezosurgery and then the bone-d® xenograft (particle size of 0.2 mm-1.0 mm) from medpark (busan, korea) will be placed, then the wound will be sutured. then a schedule will be set up to review the patient after 1, 7, 14, and 28 days to fill out questionnaires related to pain, acceptance, discomfort, satisfaction, and follow-up to orthodontic treatment.

Eligibility criteria:
inclusion criteria: 1. class i malocclusion with moderate crowding (4-6 mm of a tooth-size-arch-length-discrepancy). 2. good oral hygiene and periodontal health. 3. no severe skeletal discrepancy. 4. normal proclination for the upper and lower incisors. 5. no congenitally missing or extracted teeth (except for the third molars). exclusion criteria: 1. bimaxillary dentoalveolar severe protrusion. 2. previous orthodontic treatment. 3. subject with psychological abnormalities. 4. subject with systemic diseases.

Keywords: visual analog scale acceleration moderate crowding
study to evaluate the safety and efficacy of pep005(ingenol mebutate) gel, 0.05%, in patients with seborrhoeic keratosis

Conditions: Seborrheic Keratosis

Summary: this study is primarily designed to investigate whether treatment, once daily for up to three consecutive days, with pep005 (ingenol mebutate) gel, 0.05% will be safe and tolerable in patients with seborrhoeic keratosis on non-head locations. the secondary endpoint is to investigate the efficacy of pep005 gel, 0.05% when administered for up to three consecutive days to seborrhoeic keratosis on non-head locations.


Eligibility criteria:
inclusion criteria 1. patient is male or female and at least 18 years of age. 2. female patients must be of either: * non-childbearing potential, provided there is a laboratory confirmed serum follicle stimulating hormone (fsh) level ≥ 40miu/ml or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus); or * childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy. 3. patient has provided informed consent documented by signing the informed consent form (icf) prior to any study-related procedures, including any alteration of medications in preparation for study entry. 4. patient has agreed to allow photographs of the selected treatment lesions to be taken and used as part of the study data package. exclusion criteria 1. known sensitivity or allergy to any of the ingredients in pep005 (ingenol mebutate)gel. 2. current enrolment or participation in a clinical research study within 30 days of entry into this study.

Keywords: pep005 peplin seborrhoeic keratosis
safety and efficacy of bevacizumab plus rad001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer

Conditions: Carcinoma; Adenocarcinoma; Renal Cell; Nephroid Carcinoma; Hypernephroid

Summary: to estimate the difference in efficacy and safety of bevacizumab and rad001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.


Eligibility criteria:
inclusion criteria: 1. patients with metastatic renal cell carcinoma 2. patients with at least one measurable lesion 3. patients with progressive metastatic renal cell carcinoma 4. patients who had a prior partial or complete nephrectomy 5. patients with a karnofsky performance status ≥70%. 6. adequate bone marrow function 7. adequate liver function 8. adequate renal function 9. adequate coagulation profile exclusion criteria: 1. 4 weeks post-major surgery 2. patients who had radiation therapy within 28 days prior to start of study 3. patients in need for major surgical procedure during the course of the study. 4. patients with a serious non-healing wound, ulcer, or bone fracture. 5. patients with a history of seizure(s) not controlled with standard medical therapy. 6. patients who have received prior systemic treatment for their metastatic rcc. 7. patients who received prior therapy with vegf pathway inhibitor 8. patients who have previously received systemic mtor inhibitors 9. patients with a known hypersensitivity rad001 (everolimus) or other rapamycins or to its excipients. 10. patients with history or current central nervous system (cns) metastases or spinal cord compression. 11. patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment. 12. patients with proteinuria at screening. 13. patients with inadequately controlled hypertension 14. patients receiving ongoing or with recent need for full therapeutic dose of oral or parenteral anticoagulants or chronic daily treatment with aspirin 15. patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent. 16. patients with a known history of hiv 17. patients with hypersensitivity to interferon alfa-2a or any component of the product. 18. patients with an active, bleeding diathesis or coagulopathy or recurrent thromboembolism 19. patients who have any severe and/or uncontrolled medical conditions or other conditions 20. left ventricular ejection fraction \< lower limit of institutional normal assessed by echo or muga 21. patients who have a history of another primary malignancy ≤ 3 years 22. female patients who are pregnant or breast feeding 23. patients who are using other investigational agents or who had received investigational drugs ≤ 4 weeks prior to study treatment start. 24. patients unwilling to or unable to comply with the protocol other protocol-defined inclusion/exclusion criteria may apply

Keywords: renal cell carcinoma adults bevacizumab rad001 everolimus interferon clear roferon avastin nephrectomy newly diagnosed